Changeflow GovPing Healthcare & Life Sciences Anti-OX40 Antibodies, Ichnos Sciences, Apr 15
Routine Notice Added Final

Anti-OX40 Antibodies, Ichnos Sciences, Apr 15

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3802600A1 assigned to Ichnos Sciences S.A., covering anti-OX40 antagonistic antibodies and dosage regimens for the treatment of OX40-mediated disorders. The application names Jonathan Back and Sachin Dubey as inventors, with IPC classifications in C07K 16/28 and A61K 39/395. The application designates 30 European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 34 changes logged to date.

What changed

The EPO published application EP3802600A1 covers anti-OX40 antagonist antibodies and associated dosage regimens for treating OX40-mediated disorders. Inventors Back and Dubey filed under IPC classifications C07K 16/28 and A61K 39/395. The application designates 30 European Contracting States, indicating broad geographic protection sought.

Pharmaceutical and biotechnology companies developing immunotherapies or OX40-targeting biologics should review the application's claims for potential overlap with their own R&D programs or existing IP portfolios. Freedom-to-operate analyses may be affected for parties active in the OX40/OX40L pathway space.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ANTI-OX40 ANTAGONISTIC ANTIBODIES AND DOSAGE FOR THE TREATMENT OF OX40-MEDIATED DISORDERS

Publication EP3802600A1 Kind: A1 Apr 15, 2026

Applicants

ICHNOS SCIENCES S.A.

Inventors

BACK, Jonathan, DUBEY, Sachin

IPC Classifications

C07K 16/28 20060101AFI20191206BHEP A61K 39/395 20060101ALI20191206BHEP A61P 37/08 20060101ALI20191206BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Biopharmaceutical development Immunotherapy
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!